Merck (MSD outside of the US and Canada) has acquired Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion. Cidara’s lead candidate, CD388, consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed to prevent influenza A and B. CD388 is […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!